{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:35:05Z","timestamp":1770478505561,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,3,30]],"date-time":"2005-03-30T00:00:00Z","timestamp":1112140800000},"content-version":"vor","delay-in-days":7212,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry"],"published-print":{"date-parts":[[1985,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>By using a recently developed flow cytometric method we have analyzed cellular DNA content of paraffin\u2010embedded histological material from cancer patients. This method allows the retrospective study of tumors from patients whose clinical outcome is already known, and we have applied it to ovarian cancers, stage II breast cancers, and to metastatic adenocarcinoma of unknown primary site. In addition to knowledge of patient survival, comprehensive information was available about other prognostic determinants and treatment received, and we have used multivariate analysis in an attempt to determine the prognostic significance of cellular DNA content. In ovarian cancer, it is a major prognostic variable except in stage IV disease, whereas in metastatic adenocarcinoma of unknown primary site cellular DNA content has no influence on survival. For stage II breast cancer the situation is more complex and requires larger numbers to be studied. However, aneuploid tumors tend to have more extensive involvement of axillary lymph nodes and a poorer overall disease\u2010free survival. This influence of DNA content on disease\u2010free survival appears to be confined to premenopausal patients, and has no effect on patient survival following disease recurrence. Although we need to study more patients and more turnor types, taken together the results so far show a generally more favorable prognosis for patients with diploid tumors, except in the presence of recurrent or metastatic disease. The better prognosis associated with diploid tumors could be due to the fact that they are more commonly found in earlier clinical stages rather than to their being inherently less aggressive than aneuploid tumors.<\/jats:p>","DOI":"10.1002\/cyto.990060409","type":"journal-article","created":{"date-parts":[[2005,8,8]],"date-time":"2005-08-08T16:07:03Z","timestamp":1123517223000},"page":"327-333","source":"Crossref","is-referenced-by-count":331,"title":["Application of DNA flow cytometry to paraffin\u2010embedded archival material for the study of aneuploidy and its clinical significance"],"prefix":"10.1002","volume":"6","author":[{"given":"David W.","family":"Hedley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian W.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,16]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5795.271"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1979.168"},{"key":"e_1_2_1_4_2","first-page":"394","article-title":"Prognostic significance of nuclear DNA content in mammary adenocarcinoma in humans","volume":"44","author":"Auer G","year":"1984","journal-title":"Cancer Res"},{"key":"e_1_2_1_5_2","first-page":"3982","article-title":"Flow cytometry in clinical cancer research","volume":"43","author":"Barlogie B","year":"1983","journal-title":"Cancer Res"},{"key":"e_1_2_1_6_2","first-page":"5026","article-title":"Diagnostic and biological implications of flow cytometric DNA content analysis in lung cancer","volume":"43","author":"Bunn PA","year":"1983","journal-title":"Cancer Res"},{"key":"e_1_2_1_7_2","first-page":"4187","article-title":"Prognostic indicators including DNA histogram type, receptor content, and staging related to human breast cancer patient survival","volume":"44","author":"Coulson PB","year":"1984","journal-title":"Cancer Res"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990050419"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3"},{"key":"e_1_2_1_10_2","first-page":"397","article-title":"Influence of cellular DNA content on survival in advanced ovarian cancer","volume":"44","author":"Friedlander ML","year":"1984","journal-title":"Cancer Res"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.37.9.961"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.29"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810815)48:4<974::AID-CNCR2820480420>3.0.CO;2-#"},{"key":"e_1_2_1_14_2","first-page":"3","volume-title":"Histology","author":"Ham AW","year":"1979"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/31.11.6619538"},{"key":"e_1_2_1_16_2","first-page":"5395","article-title":"Influence of cellular DNA content on disease\u2010free survival in Stage II breast cancer","volume":"44","author":"Hedley DW","year":"1984","journal-title":"Cancer Res"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(85)90171-3"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90995-4"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841868409135997"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198407263110405"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830515)51:10<1879::AID-CNCR2820511021>3.0.CO;2-9"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810815)48:4<980::AID-CNCR2820480421>3.0.CO;2-7"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990030109"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6177.1530"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(83)90178-5"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/28.11.6159392"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF02934525","article-title":"Clinical DNA flow cytometry","volume":"1","author":"Tribukait B","year":"1984","journal-title":"Med Oncol Tumor Pharmachother"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910330404"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198007103030205"}],"container-title":["Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.990060409","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.990060409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T17:34:50Z","timestamp":1697823290000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.990060409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1985,7]]}},"alternative-id":["10.1002\/cyto.990060409"],"URL":"https:\/\/doi.org\/10.1002\/cyto.990060409","archive":["Portico"],"relation":{},"ISSN":["0196-4763","1097-0320"],"issn-type":[{"value":"0196-4763","type":"print"},{"value":"1097-0320","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,7]]}}}